参考文献
[1]Bläker H.Grading of tumors in the tubular digestive tract :Esophagus,stomach,colon and rectum[J].Pathologe,2016,37(4):293-298.
[2]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.
[3]Arnold M,Soerjomataram I,Ferlay J,et al.Global incidence of oesophageal cancer by histological subtype in 2012[J].Gut,2015,64(3):381-387.
[4]Yang Z,Zeng H,Xia R,et al.Annual cost ofillness of stomach and esophageal cancer patients in urban and rural areas in China:A multi-center study[J].Chin J Cancer Res,2018,30(4):439-448.
[5]Zeng H,Chen W,Zheng R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries[J].Lancet Glob Health,2018,6(5):e555-e567.
[6]Rice TW,Gress DM,Patil DT,et al.Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J].CA Cancer J Clin,2017,67(4):304-317.(https://www.daowen.com)
[7]Mandard AM,Dalibard F,Mandard JC,et al.Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma.Clinicopathologic correlations[J].Cancer,1994,73(11):2680-2686.
[8]Ravishankaran P,Krishnamurthy A.Prognostic value of metastatic lymph nodal ratio in squamous cell carcinoma of esophagus:A three-step extrapolative study[J].South Asian J Cancer,2014,3(4):213-216.
[9]Hechtman JF,Polydorides AD.HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma:a review of histopathology,diagnostic testing,and clinical implications[J].Arch Pathol Lab Med,2012,136(6):691-697.
[10]Bartley AN,Washington MK,Colasacco C,et al.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma:Guideline From the College of American Pathologists,American Society for Clinical Pathology,and the American Society of Clinical Oncology[J].J Clin Oncol,2017,35(4):446-464.
[11]Fuchs CS,Doi T,Jang RW,et al.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer:Phase 2 Clinical KEYNOTE-059 Trial[J].JAMA Oncol,2018,4(5):e180013.
[12]Adenis A,Kulkarni AS,Girotto GC,et al.Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181[J].J Clin Oncol,2022,40(4):382-391.